BidaskClub downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a hold rating in a research note published on Saturday.

Several other brokerages have also recently weighed in on CPRX. Zacks Investment Research cut Catalyst Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, October 11th. HC Wainwright reiterated a buy rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 10th. SunTrust Banks set a $5.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, October 31st. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $8.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $6.25.

Shares of Catalyst Pharmaceuticals (CPRX) opened at $3.92 on Friday. Catalyst Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $4.51. The firm has a market capitalization of $337.30, a price-to-earnings ratio of -18.67 and a beta of 1.68.

Hedge funds have recently modified their holdings of the business. Nationwide Fund Advisors purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $111,000. New York State Common Retirement Fund purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $114,000. State of Wisconsin Investment Board purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $149,000. SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth $144,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Catalyst Pharmaceuticals by 1,861.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 59,896 shares in the last quarter. Institutional investors and hedge funds own 34.75% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.watchlistnews.com/catalyst-pharmaceuticals-cprx-lowered-to-hold-at-bidaskclub/1800629.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.